GANX · Gain Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Eric I. Richman CHIEF EXECUTIVE OFFICER | ▲ Buy | Open Market | 289,629 Shares held | 7/1/2024 | View profile |
| Khalid Islam Director | ▲ Buy | Open Market | 50,000 Shares held | 8/9/2024 | View profile |
| Jeffrey Scott Riley Director | ▲ Buy | Open Market | 30,000 Shares held | 3/28/2024 | View profile |
| Matthias Alder Chief Executive Officer | ▼ Sell | Tax Withholding | 21,140 Shares held | 3/26/2024 | View profile |
| Gene Mack CFO and Interim CEO | ▲ Buy | Open Market | 14,400 Shares held | 8/9/2024 | View profile |
| Calabrese Salvatore CHIEF FINANCIAL OFFICER | ▲ Buy | Open Market | — Shares held | 5/19/2022 | View profile |
Transaction History
| Gene Mack | ▲ Buy | Open Market | 14,400 | $15K | 8/9/2024 |
| Khalid Islam | ▲ Buy | Open Market | 50,000 | $50K | 8/9/2024 |
| Eric I. Richman | ▲ Buy | Open Market | 5,000 | $6K | 7/1/2024 |
| Eric I. Richman | ▲ Buy | Open Market | 12,000 | $15K | 7/1/2024 |
| Jeffrey Scott Riley | ▲ Buy | Open Market | 30,000 | $116K | 3/28/2024 |
| Matthias Alder | ▲ Buy | Option Exercise | 18,750 | — | 3/26/2024 |
| Matthias Alder | ▲ Buy | Option Exercise | 825 | — | 3/26/2024 |
| Matthias Alder | ▲ Buy | Option Exercise | 637 | — | 3/26/2024 |
| Matthias Alder | ▼ Sell | Tax Withholding | 6,085 | $25K | 3/26/2024 |
| Matthias Alder | ▼ Sell | Open Market | 206 | $507 | 12/21/2023 |
| Matthias Alder | ▲ Buy | Option Exercise | 637 | — | 12/20/2023 |
| Matthias Alder | ▼ Sell | Open Market | 1,820 | $5K | 12/7/2023 |
| Matthias Alder | ▲ Buy | Option Exercise | 825 | — | 10/1/2023 |
| Eric I. Richman | ▲ Buy | Option Exercise | 54,900 | — | 9/20/2023 |
| Matthias Alder | ▲ Buy | Option Exercise | 2,550 | — | 9/20/2023 |
| Matthias Alder | ▲ Buy | Option Exercise | 3,300 | — | 7/1/2023 |
| Eric I. Richman | ▲ Buy | Open Market | 2,482 | $6K | 5/25/2022 |
| Eric I. Richman | ▲ Buy | Open Market | 9,256 | $26K | 5/20/2022 |
| Eric I. Richman | ▲ Buy | Open Market | 4,000 | $11K | 5/19/2022 |
| Calabrese Salvatore | ▲ Buy | Open Market | 3,000 | $24.3M | 5/19/2022 |
| Eric I. Richman | ▲ Buy | Option Exercise | 4,922 | $39K | 8/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO
Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO. Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.